Investment Rating - The industry investment rating is upgraded to "Overweight" [3] Core Insights - The chemical industry is expected to experience a recovery driven by both cyclical and growth factors, with a focus on organic silicon, PTA, polyester filament, caprolactam, spandex, vitamins, sweeteners, refrigerants, and phosphorus chemicals [7] - The organic silicon industry is entering a recovery phase, with new applications becoming the core growth driver. From 2019 to 2024, domestic DMC capacity expanded rapidly, leading to temporary oversupply and declining prices. However, with no new capacity expected in 2025 and increasing demand from sectors like new energy vehicles and photovoltaics, the supply-demand balance is improving [7] - The PTA and polyester filament industries are approaching a turning point, with the expansion cycle nearing its end. The demand side is expected to continue growing, supported by easing trade tensions and improved external demand [7] - The introduction of quota policies is expected to lead refrigerants into a high prosperity cycle, with supply constraints and stable demand growth from markets like heat pumps and cold chain logistics [9] - The synthetic biology sector is poised for explosive growth, driven by the transition to low-energy products and breakthroughs in non-grain bio-based materials [9] - OLED technology is accelerating its penetration into various display sizes, supported by policy measures aimed at fostering the new display industry [10] - The demand for high-frequency and low-loss electronic resins is increasing due to the rise of AI infrastructure, with AI server shipments expected to grow significantly [11] - The electronic chemicals sector is benefiting from the expansion of wafer production capacity, with increasing demand for key materials like photoresists and packaging materials [12] Summary by Sections Industry Performance - The chemical sector's overall performance ranked 14th with a weekly change of 0.78%, outperforming the Shanghai Composite Index by 0.38 percentage points [6][21] - Key stocks such as Honghe Technology and Zhongcai Technology saw significant price increases due to rising demand in AI servers and high-speed network equipment [6] Supply-Side Tracking - A total of 155 companies in the chemical industry had their production capacities affected, with 4 new repairs and 7 restarts reported [14] Key Industry Dynamics - BlueStar announced the acquisition of Elkem's core organic silicon assets, marking a strategic move to enhance its position in the global organic silicon industry [34] - The first biofuel blending policy in China was approved, allowing for local blending and reducing reliance on imports [34]

实现科技与伦理的动态适配，需从事后纠偏转向过程嵌入，将伦理原则前移至技术研发、应用部署的全 流程 脑机接口可增强认知能力，基因编辑可改变生理特征，但"为人"的关键仍是自我意识的连续性、自主决 策能力以及为决策负责的态度 "善"不是抽象的道德概念，而是要确保技术发展不偏离人类共同利益，让所有人都能从技术进步中受 益，实现人与技术的和谐共生 文 |《瞭望》新闻周刊记者 扈永顺 鲁晓：传统伦理治理多在技术成熟后进行补救，难以适应当前技术的飞速发展。实现科技与伦理的动态 适配，需从事后纠偏转向过程嵌入，将伦理原则前移至技术研发、应用部署的全流程，推动形成可解 释、可审计、可追责的技术发展路径。同时，算法决策、自动生成内容等技术打破了传统责任边 界，"谁来负责、如何负责"变得模糊，需重塑技术发展的责任体系，通过制度安排明确开发者、平台、 使用者和监管部门的责任，形成可追责、可审计、可纠偏的责任闭环，让科技向善从道德倡导化为制度 约束。 随着生成式人工智能、基因编辑、量子计算等颠覆性技术的迅猛发展，人类社会正面临着前所未有的伦 理挑战。例如生殖细胞编辑的伦理争议持续发酵；Neuralink等脑机接口涉及意识上传、记忆篡改 ...

Core Viewpoint - The article emphasizes the transformative potential of the pharmaceutical and healthcare industry, highlighting the integration of AI technology, the global expansion of Chinese pharmaceutical innovations, and the commitment to deepening investment in the sector as key drivers for future growth [3][4][6][7]. Group 1: AI Empowerment in Pharmaceutical Innovation - AI is reshaping the pharmaceutical industry by significantly reducing research and development cycles and costs, addressing traditional challenges of high investment and long timelines [4][5]. - The integration of AI in drug discovery, clinical trial design, and production processes is seen as a new paradigm that enhances the industry's productivity and innovation capabilities [4][5]. Group 2: Global Expansion of Chinese Pharmaceutical Innovations - 2025 is identified as a pivotal year for Chinese pharmaceutical companies, marking a transition from quantity to quality in global markets, with total foreign licensing transactions exceeding $130 billion and over 150 deals [6]. - Chinese companies are increasingly recognized as equal partners in global pharmaceutical competition, with significant collaborations such as the $12 billion partnership between Heng Rui Medicine and GSK [6]. Group 3: Commitment to Investment in the Pharmaceutical Sector - The investment landscape in the pharmaceutical sector is evolving, with a projected financing total of approximately 122.78 billion yuan in 2025, reflecting a 46.41% year-on-year increase [7]. - The focus remains on early-stage, innovative, and high-quality companies, particularly in areas like AI drug development and advanced medical devices, to foster growth and innovation [7][8].

2026：于临界处坚守，在折叠处重构展望 2026年，技术的快速迭代必将伴随路线的激烈竞争与优胜劣汰。我们怀抱审慎的乐观，坚信中国经 济的深厚底蕴与科技创新的巨大潜能。那些在实验室里酝酿的惊奇，在生产线上升级的工艺，终将 汇聚成推动社会进步的磅礴力量。 CAN PART ? 骏 马 启 新 · 创 赢２０２６ 证券时报。全国创投协会联盟 National Alliance of Vanture Capilal Associations 業 本书出印 科创星创始合伙 2025年，是新一轮科技革命的关键节点。我国的"十五五" 规划建议 与美国的"创世纪计划"，不约 而同地将人工智能、光子、量子、商业航天、脑机接口、可控核聚变和合成生物学等前沿技术列为 国家发展的核心目标。这标志着未来的全球竞争与发展轨迹，正清晰地向着这些硬核领域进发。 我们清晰地看到，经过过去十年的潜心摸索与积累，硬科技已度过缓慢的爬坡期，正站在加速爆 发、指数增长的临界点之上。 锚定长期：在深度调整中聚焦核心价值 2025年，也是中国创投行业经历深度调整后，走向复苏与坚定转型的一年。市场的逻辑从未如此清 晰：唯有回归"投早、投小、投长期、投硬科 ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan [6][34]. - Jintou Shengyuan aims to enhance the operational efficiency of provincial government industrial funds and contribute to the modernization of the industrial system in Zhejiang [34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%, and is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods since 2003, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector to enhance research capabilities and market penetration [15][16]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, driven by advancements in AI and automation [15][16].

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 ↓↓↓ 论坛设置 0 2 拟定话题 0 3 *以大会现场实际议程为准 商务合作 ...

纳斯达克上市公司PFAI正式入驻深港科技创新合作区—港深创科园，启动建设合成生物学实验室 及"PFAI国际生物技术创新协同中心"，其首个落地项目"人源乳铁蛋白"也开始进入中试放大阶段。这一 里程碑事件，不仅彰显了国际前沿生物企业对河套创新生态的高度认可，更与2026年深圳市政府工作报 告中关于河套发展的战略部署同频共振，为深港协同创新注入强劲动能。 更值得期待的是，PFAI的入驻将形成"高端平台+核心技术+国际资源"的聚合效应。其国际化研发团队 与资本背景，将与河套已有的国家人工智能学院深圳河套学院、中科院香港创新院基地等平台形成交叉 协同，推动"AI+生物"融合创新。同时，项目将受益于河套科研货物免税、跨境人员便利等政策红利， 加速研发与产业化进程。 深圳正以河套为支点，撬动深港科技一体化发展。PFAI作为国际生物创新企业率先落子，不仅为自身 发展开辟新空间，也为更多全球顶尖科技企业提供了"来华创新"的示范路径。随着新皇岗口岸启用、跨 境通道完善，河套的"磁吸力"将持续增强。 未来，河套深港科技创新合作区有望成为全球合成生物学与生物技术创新的重要策源地。PFAI的先行 实践，正为这一愿景写下有力注脚。在政策 ...

大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 承办单位 | 享融智云 商务合作 0 4 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 论坛设置 0 2 | | 会场一 | 会场二 | 会场三 | ...

Core Viewpoint - The article discusses the development of next-generation biomanufacturing technologies based on extreme microorganisms, particularly Halomonas bluephagenes, emphasizing their potential to achieve sustainable industrial production while addressing the challenges of traditional microbial platforms [2][3]. Group 1: Need for Biomanufacturing Transition - The biomanufacturing technology using microorganisms is increasingly recognized as an environmentally friendly alternative for producing diverse chemicals, driven by advancements in synthetic biology [8]. - Current industrial biotechnology faces limitations due to high energy-consuming sterilization processes and inefficiencies in continuous production, necessitating the shift to next-generation biomanufacturing (NGIB) using extreme microorganisms [9][10]. Group 2: Industrial Value of Extreme Microorganisms - Extreme microorganisms, such as thermophiles, acidophiles, and halophiles, exhibit remarkable growth capabilities in harsh environments, making them suitable for industrial applications [11]. - These microorganisms can significantly reduce sterilization needs and enhance production efficiency, positioning them as valuable assets in sustainable biomanufacturing [14][15]. Group 3: Development of Next-Generation Industrial Biotechnology - Halomonas bluephagenes, a halophilic bacterium, shows promise in producing biopolymers like PHB, with advantages in genetic engineering and metabolic pathway optimization [13][16]. - The development of genetic tools and adaptive evolution strategies has led to significant improvements in product yields and metabolic efficiency [17][20]. Group 4: Metabolic Engineering and Product Synthesis - Metabolic engineering is crucial for enhancing the production of target metabolites in extreme microorganisms, with strategies focusing on cell morphology optimization and dynamic control of protein degradation rates [20][21]. - Halomonas bluephagenes has been engineered to utilize various low-cost substrates, including starch and food waste, for the production of biopolymers and high-value chemicals [27][33]. Group 5: Industrial Applications and Future Directions - The NGIB technology has been successfully applied in the production of biodegradable materials like PHA and various fine chemicals, with industrial-scale implementations already underway [39]. - Future advancements will require integrating cutting-edge technologies and optimizing metabolic pathways to enhance the efficiency and sustainability of biomanufacturing processes [41][43].

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]